Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)
26.10 x 1 35.61 x 2
Post-market by (Cboe BZX)
30.06 -1.60 (-5.05%) 04/04/25 [NASDAQ]
26.10 x 1 35.61 x 2
Post-market 30.06 unch (unch) 16:02 ET
Profile for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.

Company Info

Alkermes Plc 1 BURLINGTON ROAD CONNAUGHT HOUSE DUBLIN L2 D04 C5Y6 IRL

www.alkermes.com Employees: 1,800 P: 353-1772-8000

Sector:

Medical

Description:

Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis. Alkermes derives revenues on net sales of its proprietary products: Vivitrol & Aristada, and manufacturing and/or royalty revenues on net sales of products commercialized by the company's partners. These include Risperdal Consta, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, Ampyra/Fampyra and Bydureon. Interesting late-stage candidate in the company's pipeline include nemvaleukin alfa developed for treating advanced solid tumors. Its proprietary drugs are Vivitrol & Aristada.

Key Statistics

Overview:

Market Capitalization, $K 4,954,970
Enterprise Value, $K 4,663,820
Shares Outstanding, K 164,836
Annual Sales, $ 1,558 M
Annual Net Income, $ 367,070 K
Last Quarter Sales, $ 429,990 K
Last Quarter Net Income, $ 146,500 K
EBIT, $ 421,740 K
EBITDA, $ 450,270 K
60-Month Beta 0.39
% of Insider Shareholders 4.89%
% of Institutional Shareholders 95.21%
Float, K 156,776
% Float 95.11%
Short Volume Ratio 0.43

Growth:

1-Year Return 16.47%
3-Year Return 1.45%
5-Year Return 94.82%
5-Year Revenue Growth 33.02%
5-Year Earnings Growth 3,285.71%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.04 on 02/12/25
Next Earnings Date 05/07/25
Earnings Per Share ttm 2.42
EPS Growth vs. Prev Qtr 50.82%
EPS Growth vs. Prev Year 170.59%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 05/15/00

ALKS Ratios

Ratio
Price/Earnings ttm 13.08
Price/Earnings forward 23.74
Price/Earnings to Growth 1.93
Return-on-Equity % 30.80%
Return-on-Assets % 19.09%
Profit Margin % 23.57%
Debt/Equity 0.00
Price/Sales 3.35
Price/Cash Flow 11.94
Price/Book 3.50
Book Value/Share 9.05
Interest Coverage 20.65
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades